Tag Archives: Risk Reduction

More on the Association Between Poor Oral Hygiene and Dementia / Alzheimer’s Disease Risk (NHS Choices / Journal of the American Geriatrics Society)

Posted on March 14, 2017 by Dementia and Elderly Care News

Summary Poor dental hygiene and tooth loss appear to be associated with an increased risk of developing dementia, according to research from Japan. Full Text Link Reference ‘Tooth loss link to increased risk of dementia’. London: NHS Choices; Behind the … Continue reading →

Further Press Releases and Documents Relating to the 2016 Alzheimer’s Association International Conference (Alzheimer’s Association International Conference)

Posted on August 1, 2016 by Dementia and Elderly Care News

Summary A list of press-releases is available relating to some of the main presentations at the Alzheimer’s Association International Conference, held in Toronto last week. Full Text Link Reference Alzheimer’s Association International Conference® 2016. List of Press Releases. [Toronto. Online]: … Continue reading →

Posted in Antipsychotics, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Statistics, Universal Interest | Tagged 2016 Alzheimer’s Association International Conference (AAIC®2016), ADAPT-FS Research Group, Alzheimer Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's and Dementia: The Journal of the Alzheimer's Association, Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study (ADAPT-FS), Alzheimer's Disease Neuroimaging Initiative, Alzheimer’s Association, Alzheimer’s Association AAIC Press Office, Alzheimer’s Association International Conference® (AAIC®) 2016, Alzheimer’s Disease and Related Dementias (ADRD) Milestones (United States), Alzheimer’s Disease Research in Ibero America, Amyotrophic Lateral Sclerosis (ALS), Australian Reduction in Use of Antipsychotics in Dementia Care, Avoidable Hospital Admissions, Avoidable Hospitalizations of People With Alzheimer’s Disease: Cost to Medicare (USA), Behavioural and Psychological Symptoms of Dementia (BPSD), Beta-Amyloid PET Imaging, Canadian Research: Advances in Dementia Care, Celecoxib, Celecoxib (Selective COX-2 Inhibitor), Centro de Investigatición y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Dementia Risk Prevention, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia-Related Misdiagnosis, Dementia-Related Misdiagnosis (Male), Disclosure, Disclosure of Risk Marker Status, Disclosure Protocols for Disclosing APOE Genotype for Risk of Dementia, Epidemiology of Alzheimer's disease in Ibero America, Estudio Nacional de Salud y Envejecimiento en México (ENASEM), Ethical Challenges in Preclinical Alzheimer’s Disease Studies and Trials, Ethical Considerations, Ethical Dilemmas, Ethics, Ethics and Consent, Eye Tests for Detection of Memory Decline and Dementia, Flanders-Belgian Patient Group, Formal Education and Complex Work (Cognitive Reserve), French Three-City Study, Frontotemporal Lobar Degeneration (FTLD), Genome-Wide Association Studies, Genome-Wide Association Studies (GWAS), Genome-Wide Association Study, Genotyping, Ibero America, International Genomics of Alzheimer's Project (IGAP), Latin America, Low Testosterone and Risk of Dementia, Men Receiving Dementia-Related Misdiagnoses More Than Women, Mild Behavioral Impairment (MBI), Milestones for Care and Support in U.S. National Plan to Address Alzheimer's Disease, Naproxen, Naproxen (Nonselective Cyclooxygenase [COX] Inhibitor), Neurodegeneration, Neurodegenerative Disease Research, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, p.R47H rs75932628 in TREM2 (Encoding the Triggering Receptor Expressed on Myeloid Cells 2 Gene on Chromosome 6p21), Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Reduction of Systematic Sedation in Dementia Care, Research and Development, Research and Innovation, Research Commitment, Risk Prevention, Risk Reduction, Risk Reduction (Formerly Termed Prevention by WDC), SABE (Salud Bienestar y Envejecimiento), Single SNP Associations in Flanders-Belgian AD Cohort, Smell and Eye Tests for Detection of Memory Decline and Dementia, Smell Tests For Detection of Memory Decline and Dementia, SNP rs75932628, Stopping Systemic Sedation, Systemic Sedation, Tau Pathogenesis, Tau Therapeutic Strategies, Testosterone Depletion and Increased Risk of Dementia, Three-City Study, Treating People with Alzheimer’s Disease Increases Survival and Reduces Cost of Care (vs. Non-Treatment), TREM2 R47H as a Risk Factor, USA National Plan to Address Alzheimer's Disease, Vascular Care Intervention To Prevent Dementia | Leave a comment

Significant Changes at the World Dementia Council? (WDC)

Posted on February 28, 2016 by Dementia and Elderly Care News

Summary There has been reform within the World Dementia Council (WDC). The changes are intended to make this body “more representative” in global terms (if such were possible) and fully independent. The Council now includes a wider range of international … Continue reading →

Posted in Alzheimer’s Disease International (ADI), Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, Diagnosis, For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, UK, Universal Interest, World Health Organization (WHO) | Tagged Abuse of Vulnerable Adults, Academia-Industry Partnerships, Academic Research, Alternatives to Antipsychotic Drugs, Alzheimer's Association, Alzheimer’s Disease: Risk Factors, Alzheimer’s Research UK (ARUK), Argentina, ARUK: Alzheimer’s Research UK, Assistive Technology, Associate Members (WDC), Awareness, Awareness Raising, Behavioural Risk Factors, Big Data, Big Data Partnership, Big Pharma, Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Biotechnology, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Cross-Sector Partnerships, Data Sharing, Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Friends, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Dementia Risk Factors, Dementia Risk Prevention, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, Department of Health’s Integrated Development Initiative, Digital Technology, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Yves Joanette: Scientific Director of Canadian Institute of Health Research (Institute of Aging), Emerging Technology, Enabling Technology, Future Long-Term Care Costs, GAAD: Global Action Against Dementia, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Outlook, Global Social Investment for Dementia, Government Research Funding, Hilary Doxford: World Dementia Council Member, Indonesia, Information Technology, Innovative Technology, International Collaborations, International Dementia Research Inventories, International Programmes, Interventions for Social Isolation and Loneliness in Men, Investment in Technology, Join Dementia Research, Leveraging Big Data, Lifestyle Risk Factors, Loneliness and Social Isolation, Modifiable Risk Factors, National Institute of Ageing (NIA), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, Nigeria, Open Data and Big Data, Organisation for Economic Co-operation and Development (OECD), Partnership and Collaboration, Partnership Working, Philanthropic Funding, Pipeline Databases, Prevention, Prevention of Dementia, Prime Minister’s Challenge On Dementia 2020, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Raj Long: Vice Chair of World Dementia Council, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Stigma, Regulatory Agencies, Regulatory Experts, Research and Development, Research and Innovation, Research Commitment, Research Funding, Resource and Incentives, Restraint and Restrictions, Restraint in Health and Adult Social Care, Risk Factors, Risk Reduction, Risk Reduction (Formerly Termed Prevention by WDC), Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, Social Isolation, Stigma, Taiwan, Treatment and Prevention of Dementia, US National Institute on Aging, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO), Yves Joanette: Chair of World Dementia Council | Leave a comment

National Dementia Policy: Formation of Dementia Advisory Group (Department of Health / Dementia Challenge)

Posted on December 21, 2014 by Dementia and Elderly Care News

Summary The Department of Health intends to publish a renewed “vision” for strategic direction, with plans up to 2020, on the future of dementia policy in England. It should be ready by early 2015. This will continue and extend existing … Continue reading →

Tag Archives: Risk Reduction

More on the Association Between Poor Oral Hygiene and Dementia / Alzheimer’s Disease Risk (NHS Choices / Journal of the American Geriatrics Society)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites